Arjun Masurkar, MD, PhD: Genetic Testing for Alzheimer Disease

Article

Arjun Masurkar, MD, PhD, discusses how genetic testing could usher in a new wave of diagnostics for Alzheimer disease.

Diagnosing Alzheimer disease remains a challenge despite new advancements in recent years.

In an interview with MD Magazine®, Arjun Masurkar, MD, PhD, a neurologist and assistant professor in the departments of neurology and neuroscience & psychology at NYU Langone Health, explained that genetic testing could be crucial in the next 10 years for better diagnosing patients with the disease.

MD Magazine: What do you think the role of genetic testing will be for diagnosing patients with Alzheimer disease?

Masurkar: It's possible that genetic testing could play a role in the future when we have methods to modify the disease at early stages. Alzheimer’s disease genetics are pretty complicated.

There are 2 categories of genes that are at play. There are 3 genes that are autosomal dominant, so they're highly familial and if you have the gene you will get Alzheimer’s disease.

Those are very rare less than 1% of Alzheimer’s disease is explained by those mutations by those genes. However, there have been trials looking at people who have the gene and who aren't even symptomatic yet because they might be people who would be most implicated or most would be of most benefit to a disease modifying therapy.

There are other genes that play a risk factor role they may not be have as much of an effect as an autosomal dominant gene but on average they may impact the risk of late onset Alzheimer's disease by 4, 5, 6-fold. The most popular or common one is the apolipoprotein E4 allele, which has been known for quite some time.

It's associated with increased amyloid deposition earlier on at younger ages. Right now we don't know how to harness apolipoprotein E4 for therapeutic use, but there's a lot of research going on into how apolipoprotein E leads to amyloid deposition and how that leads to Alzheimer's disease and so someday perhaps E4 targeted therapies would be a benefit.

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
Depression Screening: Challenges and Solutions at the Primary Care Level
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
HCPLive Five at APA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.